The document discusses new treatments being developed for malignant gliomas. It describes research into targeting the endoplasmic reticulum stress response pathway to induce apoptosis in glioma cells. Several new drug candidates and delivery methods are discussed, including an implantable pump being developed to provide continuous metronomic chemotherapy delivery directly to the brain tumor. Gene therapy using replication-competent retroviruses and improved immunotherapy approaches are also mentioned as promising new treatment strategies.
This is a briefing on the PD-1 and PD-L1 targeted agents. This briefing provides a summary of the agents in clinical development for the treatment of cancer. The briefing specifically focusses on the clinical and commercial development of nivolumab which includes a product profile, clinical development program and timeline, SWOT, potential issues, strategy, etc. More details on the products contained in this briefing can be obtained upon special request.
This is a briefing on the PD-1 and PD-L1 targeted agents. This briefing provides a summary of the agents in clinical development for the treatment of cancer. The briefing specifically focusses on the clinical and commercial development of nivolumab which includes a product profile, clinical development program and timeline, SWOT, potential issues, strategy, etc. More details on the products contained in this briefing can be obtained upon special request.
Introduction to Targeted Therapies in OncologyMohamed Abdulla
Describes the molecular background which represents the core for developing targeted therapies against specific biological events in malignant cellular clones.
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''Fundación Ramón Areces
Los días 15 y 16 de octubre de 2014, la Fundación Ramón Areces y la Real Academia Nacional de Farmacia, en colaboración con la Fundación de la Innovación Bankinter, reunieron en Madrid a algunos de los mayores expertos mundiales en nuevas terapias contra el cáncer. El Simposio Internacional, coordinado por la profesora y académica María José Alonso, analizó el momento actual de la lucha contra esta enfermedad. También fue un punto de encuentro para científicos de los más innovadores institutos de investigación en oncología, quienes debatieron sobre tres grandes temas: la Medicina Personalizada contra el cáncer, los nanomedicamentos en la terapia del cáncer y las terapias basadas en la inmunomodulación.
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)Will Roettger
This is a short briefing on the oncology immunotherapy PD-1/PD-L1 targeted agents currently under development. In this briefing we look at the competitive landscape, PD-1/PD-L1 product profiles, positioning, strategy, as well as a development timeline and SWOT on the BMS PD-1 blocker nivolumab. Updates to this briefing will come as newer information is discovered.
Answer four fundamental questions on how to develop the most innovative cancer immunotherapy treatments, starting with screening for lead molecules and ending with evaluation of combination therapies.
Identify Compounds that Rescue Disease Relevant Mutant Membrane ProteinsDiscoverX Corporation
Learn about diseases caused by protein misfolding and how you can screen for compounds, known as pharmacochaperones, that rescue misfolded proteins and could be used as therapeutics.
Introduction to Targeted Therapies in OncologyMohamed Abdulla
Describes the molecular background which represents the core for developing targeted therapies against specific biological events in malignant cellular clones.
Dr. Ignacio Melero - Simposio Internacional 'Terapias oncológicas avanzadas''Fundación Ramón Areces
Los días 15 y 16 de octubre de 2014, la Fundación Ramón Areces y la Real Academia Nacional de Farmacia, en colaboración con la Fundación de la Innovación Bankinter, reunieron en Madrid a algunos de los mayores expertos mundiales en nuevas terapias contra el cáncer. El Simposio Internacional, coordinado por la profesora y académica María José Alonso, analizó el momento actual de la lucha contra esta enfermedad. También fue un punto de encuentro para científicos de los más innovadores institutos de investigación en oncología, quienes debatieron sobre tres grandes temas: la Medicina Personalizada contra el cáncer, los nanomedicamentos en la terapia del cáncer y las terapias basadas en la inmunomodulación.
Oncology Immunotherapy - Nivolumab and other PD-1/PD-L1 Targeted Agents (061213)Will Roettger
This is a short briefing on the oncology immunotherapy PD-1/PD-L1 targeted agents currently under development. In this briefing we look at the competitive landscape, PD-1/PD-L1 product profiles, positioning, strategy, as well as a development timeline and SWOT on the BMS PD-1 blocker nivolumab. Updates to this briefing will come as newer information is discovered.
Answer four fundamental questions on how to develop the most innovative cancer immunotherapy treatments, starting with screening for lead molecules and ending with evaluation of combination therapies.
Identify Compounds that Rescue Disease Relevant Mutant Membrane ProteinsDiscoverX Corporation
Learn about diseases caused by protein misfolding and how you can screen for compounds, known as pharmacochaperones, that rescue misfolded proteins and could be used as therapeutics.
- Структура страницы. Когда информация бывает лишней.
- Подготовка изображения. Какие факторы поднимают конверсию.
- Адаптация страниц под источник трафика. Как создавать лояльность.
- Миграция креативов с промо-страницы на баннеры. Как выбрать важно.
- А/Б тестирование страницы. Простые приемы из практики.
Доклад на конференции Optimization 2016.
Amy Cueva, Founder of Mad*Pow and Co-Chair of HxRefactored explains how research can provide us with the rich and valuable insights needed to improve health experiences. She explores how emotion and empathy can inspire the work we do in health, motivating us to continue to rise to the challenge of making change in health.
10 conseils pour recruter un collaborateur efficace pour son auto école !bpermis
Voici quelques conseils pratiques pour mieux recruter pour votre auto école !
------------------------------------------
Lien vers l'article plus complet : http://www.b-permis.fr/espace-professionnel/gerer-son-auto-ecole/92-gerant-d-auto-ecole-comment-lutter-contre-ceux-qui-font-du-black.html
-----------------------------------------
Gérant d'auto-école télécharger mes 5 conseils pour mieux gérer votre auto école : http://www.b-permis.fr/guide-gerant.html
---------------------------------------------
QUI EST Cédric de B Permis Pro ?
Entrepreneur Investisseur martiniquais, je découvre le monde des auto-école par hasard.
En effet, durant mes études (c'était il y a longtemps) je suis amené à développer un logiciel de gestion pour auto-école.
Ce développement me passionne, et de fils en aiguilles, j'apprends les ficelles du métier en cotoyant des gérants et des moniteurs d'auto-école d'expérience.
En 2005, mon ancien moniteur, me propose une association pour que je l'aide à développer ses auto-écoles.
Je m'occuperai de toutes les parties marketing, informatisation et gestion administrative. Il pourra ainsi se concentrer sur les parties plus pédagogiques.
En 2009, nous décidons de lancer le site B Permis Pro pour partager notre passion du métier avec les élèves, les moniteurs et les gérants.
Ce site à notre grande surprise, devient un des sites leaders francophones.
Pour en savoir plus : http://www.b-permis.fr
Fantastic work from home opportunity
Earn money whilst saving yourself friends and family money on their holidays.
Take control of your income Take control of your future
Aim of this ppt presentation:
To understand the standard of care for both GBM and anaplastic glioma.
To know what is the new advances and modifications to the standard of care?
Contents:
Introduction: 2 slides.
GBM:
Epidemiology: 1 slide.
Molecular biology & New trends: 5 slides
EORTC/NCIC trial: 10 slides.
MGMT: 1 slide.
Evidence-based medicine: 6 slides.
Avastin in GBM: 2 slides.
Novocure (TTF): 2 slides.
Gliadel (BCNU) wafers: 1 slide.
Anaplastic astrocytoma: 7 slides
Take home message.
Presented by Matthew Rioth, MD, MS. Presented at the 2018 Eyes on a Cure: Patient & Caregiver Symposium, hosted by the Melanoma Research Foundation's CURE OM initiative.
Accelerating the Delivery of New Treatments for Children with Neuroblastoma 2...Scintica Instrumentation
Neuroblastoma is a tumour arising from anomalies in the development of the sympathic nervous system and still accounts for 13% of all cancer-related death in children due to resistant, relapsing and metastatic diseases. There is an urgent need for the development of new treatment against high-risk relapsed neuroblastoma.
Overview:
Here we will discuss the ICR Paediatric Mouse Hospital approach which integrates more advanced mouse modelling, such as the use of genetically-engineered mouse (GEM) models and patient-derived xenografts to accelerate the discovery and evaluation of novel therapeutic strategies and help shape the clinical trial pipeline priorities for children with high-risk relapsing/refractory neuroblastoma.
We will also highlight the pivotal role of MRI within the Mouse Hospital which includes:
Enhancing and accelerating preclinical trials
Quantitatively inform on tumour phenotype and tumour response to treatment to:
Develop in vivo models that emulate the clinical treatment resistant phenotype using chemotherapy-dose escalation protocol
Characterize tumour spatial heterogeneity and evolution over treatment and guide the pathological and molecular characterization of the resistant phenotype
Finally we will also discuss how the compact, cryogen-free and user-friendly Aspect Imaging M-Series has transformed our way of working within the mouse hospital by providing a shared and easily accessible resource for tumour screening (with minimal onboarding) .
Chemotherapy Friends or Foe to Cancer Immunotherapy by Prof. Mohamed L. SalemProf. Mohamed Labib Salem
This talk is presented by Mohamed Labib Salem, Ph.D.; Prof. of Immunology; Director, Center of Excellence in Cancer Research, Tanta University, Egypt
at the 15TH INTERNATIONAL CONFERENCE ON CHEMISTRY AND ITS ROLE IN DEVELOPMENT (15TH ICCRD), August 9, 2021
Faculty of Science, Mansoura University, Egypt
Richard Carvajal, MD presents Targeted Therapy for Uveal Melanoma and the Uveal Melanoma Clinical Research Landscape at the 2017 CURE OM Patient & Caregiver Symposium.
SciTech Development pitch deck including company overview, proprietary technology, lead drug ST-001 nanoFenretinide, patents, addressable market sizes, competiton, key personnel, advisory board, drug product characteristics, fenretinide history, cancer indications and drug mechanism of action (MOA).
ST-001 NanoFenretinide - SciTech Development Lead Drug CompoundSciTech Development
SciTech’s lead compound, ST-001, is a small-molecule immune oncology (IO) nanoFenretinide cancer drug employed as an aqueous nanoparticle suspension for IV administration. The ST-001 nanoFenretinide drug is comprised of the active pharmaceutical ingredient (API) fenretinide in a patented combination with carefully selected phospholipids (inactive ingredients). ST-001 is designed to deliver a 15-fold higher drug to lipid ratio and a >6x concentration of the API than conventional IV formulations achieving therapeutically effective doses without the toxic side effects observed with other delivery systems – a benefit previously unattainable. Recent discovery of the API’s immunotherapeutic effect, in which a reactivated natural immune response compliments the previously understood safe, direct, chemotherapeutic effect (functioning as dual mechanisms of action), has added materially to its value as a versatile therapeutic.
In this presentation, I discuss a new standard of treatment in cancers which is immunotherapy. I also discuss the few cancers for which it has been approved.
Clinical Trials in BNCT at the MIT Research Reactor
Dr. Thomas Chen, UCI grand rounds 7-28-2010
1.
2.
3. Typical Treatment Course for Gliomas 1. Surgery-biopsy or resection 2. Radiation with low dose temozolomide (TMZ) 3. High dose or metronomic TMZ alone 4. F/u with MRI scans every two months 5. If MRI documented progression: Avastin, repeat resection, radiosurgery, or clinical trials
15. Targeting the Perinecrotic Rim in Glioblastoma Multiforme via Modulation of the Endoplasmic Reticulum Stress Response Vascularized Periphery Perinecrotic Rim (Pseudopalisades ) Necrotic Area Thrombotic Vessel
16. Targeting the Perinecrotic Rim in Glioblastoma Multiforme via Modulation of the Endoplasmic Reticulum Stress Response
17.
18.
19. Targeting the Perinecrotic Rim in Glioblastoma Multiforme via Modulation of the Endoplasmic Reticulum Stress Response
32. TMZ treatment with 15% BSA Treatment in 6well plate and transfer to 96well plate for MTT analysis 2009-10-01 TMZ (uM) % O.D. at 490nm TMZ (uM) % O.D. at 490nm Conclusion: TMZ is not cytotoxic to CSC. U251 w/ 15% BSA CSC w/ 15% BSA 0 20 40 60 80 100 120 0 10 20 30 40 50 60 70 80 90 100 0 20 40 60 80 100 120 0 10 20 30 40 50 60 70 80
33. Is DMC Cytotoxic To Glioma Cancer Stem Cells (GCSC) ? U87 U251 CSC (single) CSC (sphere) DMC (uM) % O.D. at 490nm Condition: Medium +10% BSA, 48hr treatment 0 20 40 60 80 100 120 140 0 10 20 30 40 50 60 70 80 90 100
34. Does DMC Enduces ER Stress in Glioma Cancer Stem Cells (CSC) ? 1 2 3 4 5 GRP78 Chop Actin 1: No treatment 2: DMC 20uM 3: DMC 40uM 4: DMC 60uM 5: DMC 80uM
35. Does DMC Induce ER Stress in Glioma Cancer Stem Cells (CSC) ? 1 2 3 4 5 GRP78 Chop Actin Parp MGMT Conclusion: ER stress upregulated at DMC 60 uM in CSC. DMC at 60 uM reduces MGMT levels. 24hr treatment Cl. parp Parp 1: No treatment 2: DMC 20uM 3: DMC 40uM 4: DMC 60uM 5: DMC 80uM CSC-D431
36.
37.
38.
39.
40. May/2006 Dec/2006 Fibrillary Astrocytoma grade II ______________________________________________________________________________________________________________________________________ May/2008 Jun/2007
41. JAN / 2007 MAY / 2008 Recurrente Anaplastic Oligodendroglioma ______________________________________________________________________________________________________________________________________ NOV / 2008
42. Disease-free survival (6 months) ______________________________________________________________________________________________________________________________________ The median PFS rate was 48.2% for patients with GBM, 60% for patients with AA, and 66.6% for patients with AO.
50. www.pharmaco-kinesis.com Convection Enhanced Trials 1. Some success in Phase I/II trials 2. No clear success in Phase III trials (Neopharm, Transmid) 3. Question: Lack of success from delivery or from drug?
63. Cir. And Reservoir Pump ( Bartels ) Active Valve ( Bartels ) Flow Sensor ( Sensirion ) Pressure Sensor Temperature Sensor ( GE ) pH Sensor ( WPI ) Reservior ( Metal Bellows ) www.pharmaco-kinesis.com
64. www.pharmaco-kinesis.com Wireless Radio High level goals High level tasks Internal states Growth signal Intracranial pressure Tissue condition Tissue metabolism Table of parameters Circulate Inject 1 Inject 2 Inject 3 Pump Pump-valve Pump-valve Pump-valve VEGF Spectrometer Pressure sensor pH sensor Oxygen sensor Solid Tumor Microcontroller Medication Tumor Fluid
65.
66. www.pharmaco-kinesis.com Avastin in 28-day pump Implantated IP CPT-11 D7 – D11 D14 – D118 D21 – D25 D28 – D32 1 st dose of Avastin 2nd dose of Avastin
67.
68.
69.
70. U87 intra-cerebral glioma model for in vivo analysis of RCR vector-mediated suicide gene therapy Establishment of tumor 1 x 10 t.u. ACE-CD injected into tumor 4 Intraperitoneal injection of 5-FC H&E / IHC Survival analysis virus spread 2 x 10 U87 tumor cells injected into nude mice 5